Navigation Links
Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value
Date:2/26/2009

gram (304) and two Ambulatory Blood Pressure Monitoring (ABPM) studies (111 and 112), which showed naproxcinod's favorable 24-hour blood pressure profile. - Signature of two commercial supply agreements for naproxcinod with world leading manufacturing companies: DSM for the production of active pharmaceutical ingredient (API) and Capsugel for the production of naproxcinod capsules. - Further progress in the collaboration with Merck & Co., Inc., following the initiation of a series of phase 1b studies in mild to moderate hypertensive volunteers, which have the aim of selecting the most appropriate compound to advance into phase 2. - Two phase 2 studies for PF-03187207 in glaucoma patients conducted by Pfizer Inc demonstrated an improvement over Xalatan(R) 0.005%, in terms of intraocular pressure lowering, but did not reach statistical significance on the primary endpoint.

Eric Castaldi, Chief Financial Officer of NicOx, commented: "As planned, we successfully completed the phase 3 clinical program for naproxcinod in 2008. We believe that the attractive profile of naproxcinod achieved in the phase 3 program should ensure our compound's future commercial success. Our balance sheet has enabled us to continue to expand the pre-commercialization activities for naproxcinod in parallel with the ongoing partnering discussions. We project cash burn will substantially decline throughout 2009, following the completion of the phase 3 program, and we currently believe we have sufficient cash to finance the activities of the Company until the end of 2010. This projection does not include the possible upfront and milestone payments we expect from a potential commercialization agreement for naproxcinod."

Financial summary of 2008

Revenues for the full year 2008 were EUR3.4 million, compared to EUR20.6 million in 2007. These
'/>"/>

SOURCE NicOx
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Arpida Announces Full Year 2008 Financial Results
2. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
3. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
4. American Oriental Bioengineering, Inc. to Report Fourth Quarter and Full Year 2008 Financial Results on March 9, 2009
5. Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent
6. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
7. CV Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results
8. Human Genome Sciences to Sponsor Conference Call to Discuss Full Year 2008 Financial Results
9. Adolor Corporation to Host Investor Conference Call to Report 2008 Financials and Provide an Update on the Launch of ENTEREG(R) (alvimopan)
10. BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
11. Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014  Sigma-Aldrich Corporation (NASDAQ: SIAL ) ... its investment in Green Chemistry and donated more than ... year, the Company announced Monday in its new ... World? The report comes in a ... a responsible corporate citizen, including recognition for the second ...
(Date:7/29/2014)...  United Therapeutics Corporation (NASDAQ: ... for the second quarter ended June 30, 2014. ... our medicines are reaching increasing numbers of ... said Martine Rothblatt, Ph.D., United Therapeutics, Chairman ... this quarter of our extended-release tablet called ...
(Date:7/29/2014)... San Diego, CA (PRWEB) July 29, 2014 ... added to Pipette.com’s centrifugation product selection. Eppendorf 5427 R ... reverse engineering, and DNA – it is targeted towards ... the Eppendorf Centrifuge 5427 R as it compliments their ... as their Eppendorf line of microcentrifuge tubes, PCR tubes, ...
(Date:7/29/2014)... 29, 2014 White papers by ... cloud based eClinical technologies, have been published by leading ... follow a long line of white papers by Clinovo ... Life Science Leader, Pharmaceutical Online, and OpenHealthNews. , At ... paper by CTO Marc Desgrousilliers, 'The Five Essentials ...
Breaking Biology Technology:Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13International Pipette Distributor, Pipette.com Announces the Addition of the Eppendorf Centrifuge 5427 R to Their Product Portfolio 2Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 2Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 3
... Hefty has seen blue-ribbon government panels come and go ... thick file of reports spanning 20 years of commissions, ... thoughtful research papers is only useful if it leads ... Hefty, who retired last year from Blue-Cross/Blue Shield United ...
... Role in Community...promotes entertainment everywhere on any device ... approval for the sale of the companys desktop products ... (SPD) The transaction is now complete and Sony Pictures ... it will keep the companys employee base in Madison ...
... alternative energy , ,Madison, WI - WE Energies ... two developers that will build three wind farms increasing ... by 400%. , ,Under the agreement, the two developers, ... LLC, based in Chicago, will provide their entire energy ...
Cached Biology Technology:Governors Growth Council hopes to go light on paperwork and heavy on ideas 2Governors Growth Council hopes to go light on paperwork and heavy on ideas 3Sony Completes Acquisition of Sonic Foundry 2Sony Completes Acquisition of Sonic Foundry 3WE Energies Is Not Letting Wind Power Blow Away 2
(Date:7/29/2014)... UC San Francisco is the first to show that ... accelerate cellular aging, these negative effects may be reduced ... , "The study participants who exercised, slept well ... ones who didn,t maintain healthy lifestyles, even when they ... Puterman, PhD, assistant professor in the department of psychiatry ...
(Date:7/28/2014)... U.S. Food and Drug Administration (FDA) for other purposes ... inside human cells, including those that cause Legionnaires, disease, ... mBio , the online open-access journal of the ... identifying non-antibiotic drugs that could one day help curb ... the list inhibit the growth of at least three ...
(Date:7/28/2014)... signs of damage from the Deepwater Horizon oil spill expands ... of Mexico. The discovery was made by a team led ... A paper describing this work and additional impacts of human ... published during the last week of July 2014 in the ... National Academy of Sciences . , "The footprint of the ...
Breaking Biology News(10 mins):Healthy lifestyle may buffer against stress-related cell aging, study says 2New route to identify drugs that can fight bacterial infections 2Impact of Deepwater Horizon oil spill on coral is deeper and broader than predicted 2
... comparing the immune responses of both, young and old ... of macrophages, one of the major cell populations involved ... aged mice. This decline in the number of fighters ... be responsible for the age-associated increase in susceptibility to ...
... 2010 Burnham Institute for Medical Research (Burnham) announced ... million to support and further expand and accelerate the ... been renamed the Sanford-Burnham Medical Research Institute. This is ... 2007, he directed $20 million through Sanford Health to ...
... FAIRFAX, Va.Nearly 5,300 physicians, scientists and allied health ... Interventional Radiology,s 35th Annual Scientific Meeting March 13󈝾 ... are scheduled for 9󈝶:30 a.m. on both Monday, ... Annual Scientific Meeting offers ...
Cached Biology News:Rejuvenating the old immune system 2T. Denny Sanford donates $50 million to Burnham Institute for Medical Research 2Press registration open for Society of Interventional Radiology’s 35th Annual Scientific Meeting 2
Rabbit Anti-Ferret Whole Serum Antibody, Unconjugated...
... microPET R4 is the lowest priced, ... in the world. Despite the microPET ... competing systems in all performance categories; count ... feature set., microPET is a dedicated small ...
... product has been developed to significantly increase ... proteins. Stability is increased at room ... centigrade. This product is subjected to ... or azide. This formulation insures consistently ...
... utilizies CTI Molecular Imaging's proprietary Focus™ ... sensitivty, and a large imaging volume ... to image multiple mice or large ... a dedicated small animal PET (Positron ...
Biology Products: